Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Combining B-cell receptor antagonists and venetoclax in CLL

Richard Furman • 10 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Umbralisib Venetoclax Zanubrutinib

Richard Furman, MD, of the Weill Cornell Medical College, New York, NY, outlines the benefit of combining B-cell receptor antagonist and venetoclax to provide a synergistic effect in chronic lymphocytic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Richard Furman

5:39
Acalabrutinib monotherapy in mature B-cell malignancies
Richard Furman • 10 Jun 2020
3:43
BTK inhibtors in CLL
Richard Furman • 10 Jun 2020
17:52
Diagnosis and Initial Treatment of CLL
Peter Hillmen et al. • 12 May 2017

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals